<DOC>
	<DOCNO>NCT02287025</DOCNO>
	<brief_summary>Randomized trial evaluate impact healthcare provider ( clinician nursing staff ) support education treatment discontinuation rate absence progression patient metastatic colorectal cancer treat regorafenib . Intensified education support provide application iPad automatic link grade , dose reduction side effect management , well , reference additional article .</brief_summary>
	<brief_title>A Phase 4 Study Regorafenib Metastatic Colorectal Cancer - Does Educating Physicians Change Patient Out Comes ?</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>Histologically cytologicallyproven metastatic CRC decision treatment regorafenib make Previous treatment fluoropyrimidine , oxaliplatin irinotecanbased chemotherapy , antiVEGF therapy , , KRAS wild type , antiEGFR therapy Male female patient ≥ 18 year age Eastern Cooperative Oncology Group performance status ( ECOG PS ) 0 1 Signed inform consent obtain study specific procedure performed.Patients must able understand willing sign write ICF . Life expectancy least 12 week Adequate bone marrow , liver renal function assess follow laboratory requirement : 1 . Total bilirubin ≤ 1.5 x upper limit normal ( ULN ) 2 . Alanine aminotransferase ( ALT ) aspartate aminotransferease ( AST ) ≤ 3.0 x ULN ( ≤ 5 x ULN patient liver involvement cancer ) 3 . Alkaline phosphastase limit ≤ 2.5 x ULN ( ≤ 5 x ULN patient liver involvement cancer ) 4 . Lipase ≤ 1.5 x ULN 5 . Amylase ≤ 1.5 x ULN 6 . Serum creatinine ≤ 1.5 x ULN 7. International normalize ratio ( INR ) ≤ 1.5 x ULN partial thromboplastin time ( PTT ) activate partial thromboplastin time ( aPTT ) ≤ 1.5 x ULN unless receive treatment therapeutic anticoagulation . Patients treat anticoagulant ( e.g. , heparin ) , allow participate provide prior evidence underlie abnormality parameter exist . Close monitoring least weekly evaluation perform INR PTT stable base predose measurement define local standard care . 8 . Platelet count ≥ 100000 /mm3 , hemoglobin ( Hb ) ≥ 9 g/dL , absolute neutrophil count ( ANC ) ≥ 1500/mm3 . Blood transfusion meet inclusion criterion allow . Estimated creatinine clearance ( CLcr ) ≥ 30 mL/min calculate use CockroftGault ( CG ) equation . Women childbearing potential must blood urine pregnancy test perform maximum 7 day start study treatment , negative result must document start study treatment . Women childbearing potential men must agree use adequate contraception enter program least 8 week last study drug administration . Unable swallow oral medication . Prior use regorafenib Previous assignment treatment study . Patients permanently withdraw study participation allow reenter study . Uncontrolled hypertension ( systolic blood pressure &gt; 140 millimeter mercury ( mmHg ) diastolic pressure &gt; 90 mmHg despite optimal medical management ) Active clinically significant cardiac disease include : 1 . Congestive heart failure New York Heart Association ( NYHA ) &gt; Class II 2 . Active coronary artery disease 3 . Cardiac arrhythmia require antiarrhythmic therapy beta blocker digoxin 4 . Unstable angina ( anginal symptom rest ) , newonset angina within 3 month randomization , myocardial infarction within 6 month randomization Evidence history bleed diathesis coagulopathy , irrespective severity Any hemorrhage bleeding event &gt; National Cancer Institute Common Terminology Criteria Adverse Events ( NCICTCAE ) Grade 3 within 4 week prior start study medication Arterial venous thrombotic embolic event cerebrovascular accident ( include transient ischemic attack ) , deep vein thrombosis pulmonary embolism within 6 month start study medication ( except adequately treat catheterrelated venous thrombosis occur one month start study medication ) Previously untreated concurrent cancer distinct primary site histology colorectal cancer except cervical cancer insitu , treat basal cell carcinoma , superficial bladder tumor . Patients survive cancer curatively treat without evidence disease 3 year randomization allowed.All cancer treatment must complete least 3 year prior study entry ( i.e. , signature date ICF ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>